echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Symposium on development strategy of nanobiology held in Shenzhen

    Symposium on development strategy of nanobiology held in Shenzhen

    • Last Update: 2017-05-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [conference forum of China Pharmaceutical network] recently, the kick-off meeting of "three projects" of Shenzhen Second People's Hospital, a team of academician Yan Xiyun of Chinese Academy of Sciences, and the Symposium on development strategy of nanobiology discipline were held in Shenzhen The two sides will carry out in-depth cooperation in the research of nano drug delivery system for the treatment of NPC, nano visualization of bladder cancer, research and development of nano enzyme diagnostic kit for breast cancer, and promote the development of disciplines and personnel training with projects (photo source: Baidu photo) According to the introduction, in the future, the transformation Medical Research Institute of Shenzhen Second People's hospital will continue to integrate the internal research team of the hospital, carry out in-depth substantive scientific research cooperation with the academician Yan Xiyun of the Chinese Academy of Sciences, and make innovative achievements in the research of diagnosis and treatment of major diseases, transformation of medical scientific and technological achievements, etc Based in Shenzhen and with a global perspective, the Research Institute will strive to build a transformation medicine research center with a certain international scientific and technological influence The Institute of biophysics of the Chinese Academy of Sciences is the National Basic Research Institute of life sciences, founded in 1958 Its predecessor is the Beijing Institute of experimental biology established in 1957 The strategic orientation of the Institute of biophysics is to give full play to the comprehensive advantages of interdisciplinary, to achieve fundamental, forward-looking and strategic breakthroughs in the frontier fields of protein science, brain and cognitive science, infection and immune science, non coding nucleic acids and protein and peptide drugs, to strengthen the innovation and development of key equipment in the field of life science, and to realize the key technologies and experimental methods Focus on breakthroughs, build a transformation research system focusing on biopharmaceutical and in vitro diagnosis, and play the role of source innovation and backbone in the national innovation system   Since its establishment, under the leadership of the older generation of scientists such as Bei Shizhang, Zou Chenglu, Liang Dongcai and Yang Fuyu, and through the hard work of several generations of scientific and technological workers, the Institute has created and promoted the research of China's cell biology, radiobiology, cosmobiology, enzymology, structural biology, membrane biology, neurobiology, biological cybernetics and Biophysical Engineering Technology And development, has created a group of scientists, made a number of high-level research results, developed a number of high-tech products, incubated and established a number of high-tech companies, created good social and economic benefits, and made an important contribution to the development of national life science The second people's Hospital of Shenzhen (Affiliated Hospital of Shenzhen University) transformation Medical Research Institute was established in October 2016 The administrative department is the first level Department of the hospital, which has the characteristics of sex, openness and public welfare Its function orientation is to provide the medical technology departments and social peers with scientific and technological resources subdivision and specialized services, comprehensive technical services, innovation and entrepreneurship services The research institute establishes and develops the innovation mode of chain reaction of "clinical demand scientific research tackling clinical verification popularization and application" Through integration, integration and optimization of scientific and technological resources, integration and development of advantageous resources, and combination of relevant enterprises, it provides technical service platform for basic research and transformation medical research and development of hospital medicine.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.